Traditional chinese medicine composition for treating severe pneumonia and use thereof

Abstract

Disclosed is a traditional Chinese medicine composition for treating severe pneumonia, comprising the following crude medicinal materials: 6-12 parts by weight of ephedra, 20-40 parts by weight of gypsum, 10-15 parts by weight of almond, 15-25 parts by weight of Poria cocos, 6-12 parts by weight of dried ginger, 4-8 parts by weight of Asari Radix et Rhizoma, 10-15 parts by weight of Schisandrae Chinensis Fructus, 4-8 parts by weight of Coptidis Rhizoma, 10-20 parts by weight of Pinelliae Rhizoma, 10-15 parts by weight of Snakegourd Peel, 10-15 parts by weight of bark of magnolia, 8-12 parts by weight of Descurainiae Semen, and 8-12 parts by weight of Jujubae Fructus. The traditional Chinese medicine composition is specifically indicated for treating severe pneumonia manifested by fluid binding with heat at the chest and diaphragm as the core pathological mechanism, and has the effects of clearing lung heat and dispersing lung qi, and expelling fluid and relieving asthma.

Description

A traditional Chinese medicine composition for treating severe pneumonia and its application Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition for treating severe pneumonia and application thereof. Background Art

[0002] Severe pneumonia is a common, severe respiratory infection characterized by rapid progression and a high mortality rate, reaching 25%-50%. According to relevant studies, the pneumonia mortality rate per 100,000 people increases rapidly with age, reaching as high as 31.7% among those aged 65-74. Patients with severe pneumonia face enormous medical costs from the moment they enter the ICU, placing a significant financial and psychological burden on patients and their families. Refractory hypoxia is a major cause of early mortality in severe pneumonia, and it remains difficult to correct in the short term despite aggressive antimicrobial therapy and mechanical ventilation. This presents a significant challenge in the current comprehensive treatment of severe pneumonia, necessitating the development of effective treatments. Currently, antibiotics remain the cornerstone of Western medicine treatment for severe pneumonia, with steroids and extracorporeal membrane oxygenation also being used. However, the emergence of persistent hypoxia, the prevalence of drug-resistant bacteria, the frequent use of antibiotics, and the difficulty in developing new antimicrobial agents have led to limitations in Western medicine's treatment of severe pneumonia. Traditional Chinese medicine divides severe pneumonia into multiple syndromes, including phlegm-dampness obstructing the lungs, phlegm-heat accumulating in the lungs, heat trapped in the pericardium, and pathogenic factors trapping the body and escaping from the body. However, through theoretical research and summary and analysis of clinical cases, it was found that the combination of water and heat is the basic pathogenesis of severe pneumonia.

[0003] Traditional Chinese Medicine (TCM) believes that the lungs govern regulation, govern qi, and are the source of water—all three complement each other, working together to achieve the normal metabolism of qi and water. When pathogenic factors interact, leading to dysfunction in these functions, the body's qi-water metabolism becomes disrupted, with manifestations first manifesting in the affected area. Both the Yellow Emperor's Classic of Internal Medicine and the Treatise on Febrile Diseases discuss the pathogenesis of severe pneumonia. The Six-Channel Syndrome Differentiation in the Treatise on Febrile Diseases presents the following developmental pattern: ① Heat enters the lungs and chest, manifesting as "thirst, diarrhea, or wheezing," "wheezing and sweating," and "chest congestion." The Yellow Emperor's Classic of Internal Medicine states that "the lungs belong to the metal element," and when the lungs are affected, ② water and heat combine in the chest and diaphragm, resulting in symptoms such as "coughing and chest fullness," "shortness of breath, irritability, and inability to sleep." Heart fire, unable to overcome this, overtakes the heart. Furthermore, the lungs, situated in a yang position, are "the yin element within the yang," and "the lungs govern dryness," easily manifesting as dryness and heat. When lung metal is affected by pathogenic factors, on the one hand, body fluid production is depleted, manifesting as irritability, restlessness, and thirst; on the other hand, the spleen's transport and transformation of water to the lungs is hindered, leading to abnormal accumulation of water in the lungs. Ultimately, the combination of water and heat creates a pathological state of water-heat entanglement, the primary pathogenesis of severe pneumonia.

[0004] The current complexity of TCM syndrome types hinders clinical application. Furthermore, when severe pneumonia requires a comprehensive treatment plan combining traditional Chinese and Western medicine, this complex set of syndrome types hinders the assessment of clinical efficacy. Therefore, a key entry point for TCM treatment of severe pneumonia is to combine modern advanced medical technology and research progress, address the current difficulties in treating severe pneumonia, and develop a relatively simple, effective, and clinically feasible treatment method that aligns with the core TCM etiology and pathogenesis of severe pneumonia.

[0005] Summary of the Invention

[0006] The purpose of the present invention is to provide a traditional Chinese medicine composition (hereinafter referred to as Qingjin Pingchuan prescription) for treating severe pneumonia and its use, to evaluate its clinical efficacy based on clinical indicators such as the mortality rate of patients on the 28th day before and after treatment, the clinical improvement time within 28 days, the clinical improvement rate on days 7, 14 and 28, the duration of mechanical ventilation (days), the duration of oxygen therapy (days), and the duration of hospitalization (days), to further study the effectiveness of Qingjin Pingchuan prescription for severe pneumonia, and to provide a scientific basis for its clinical application.

[0007] The first aspect of the present invention provides a traditional Chinese medicine composition for treating severe pneumonia, which is composed of the following raw materials in parts by weight:

[0008] 6-12 parts of ephedra, 20-40 parts of gypsum, 10-15 parts of apricot kernel, 15-25 parts of poria, 6-12 parts of dried ginger, 4-8 parts of asarum, 10-15 parts of schisandra chinensis, 4-8 parts of coptis chinensis, 10-20 parts of pinellia, 10-15 parts of trichosanthes peel, 10-15 parts of magnolia bark, 8-12 parts of scutellaria baicalensis seeds, and 8-12 parts of jujube.

[0009] Furthermore, the traditional Chinese medicine composition for treating severe pneumonia is composed of the following raw materials in parts by weight:

[0010] 9-12 parts of ephedra, 30-40 parts of gypsum, 12-15 parts of apricot kernel, 20-25 parts of poria, 9-12 parts of dried ginger, 6-8 parts of asarum, 12-15 parts of schisandra chinensis, 6-8 parts of coptis chinensis, 15-20 parts of pinellia, 12-15 parts of trichosanthes peel, 12-15 parts of magnolia bark, 10-12 parts of scutellaria baicalensis seeds, and 10-12 parts of jujube.

[0011] Furthermore, the traditional Chinese medicine composition for treating severe pneumonia is composed of the following raw materials in parts by weight:

[0012] 9 parts of Ephedra, 30 parts of Gypsum, 12 parts of Apricot Kernel, 20 parts of Poria, 9 parts of Dry Ginger, 6 parts of Asarum, 12 parts of Schisandrae Chinensis, 6 parts of Coptis Rhizome, 15 parts of Pinellia, 12 parts of Fructus Trichosanthis, 12 parts of Magnolia Bark, 10 parts of Lecithin Seeds, and 10 parts of Jujube.

[0013] Furthermore, the severe pneumonia is a severe pneumonia with the core pathogenesis being the interaction of water and heat in the chest and diaphragm.

[0014] The second aspect of the present invention provides a method for preparing the above-mentioned traditional Chinese medicine composition for treating severe pneumonia, comprising the following steps:

[0015] a) Weigh each medicinal material according to the raw material ratio, add pure water to cover the medicinal materials, and soak the medicinal materials in the water for 30-35 minutes;

[0016] b) boiling the soaked medicinal materials for the first time, filtering, and collecting the primary filtrate and medicinal residue;

[0017] c) adding 400-450 mL of water to the residue for secondary decoction, and collecting the secondary filtrate;

[0018] d) combining the primary filtrate and the secondary filtrate to obtain the Chinese medicine composition liquid.

[0019] Furthermore, the volume of the pure water covering the medicinal materials in step a is 500-550 ml.

[0020] Furthermore, in the first decoction process in step b, the medicinal materials are heated to boiling and kept at a slight boil until the volume of the primary filtrate is 200-210 mL.

[0021] Furthermore, in the second decoction process in step c, the medicinal residue is heated to boiling and kept at a slight boil until the volume of the secondary filtrate reaches 150-160 mL.

[0022] The third aspect of the present invention provides a Chinese medicine preparation having the above-mentioned Chinese medicine composition for treating severe pneumonia as an active ingredient, wherein the Chinese medicine preparation is prepared into a commonly used dosage form in pharmacy using conventional preparation methods in the art.

[0023] Furthermore, the dosage form of the Chinese medicine preparation is decoction, tablet, capsule, granule, pill, mixture, oral liquid or syrup.

[0024] Furthermore, the traditional Chinese medicine preparation also includes pharmaceutically acceptable excipients.

[0025] A fourth aspect of the present invention provides a use of the above-mentioned traditional Chinese medicine composition in the preparation of a medicament for treating severe pneumonia.

[0026] The fifth aspect of the present invention provides a use of the above-mentioned traditional Chinese medicine preparation in the preparation of a medicine for treating severe pneumonia.

[0027] The Qingjin Pingchuan prescription provided by the present invention is mainly used to treat severe pneumonia with the core pathogenesis of water-heat binding in the chest and diaphragm. It has the following effects: clearing away lung heat and gradually relieving asthma.

[0028] In the Qingjin Pingchuan prescription provided by the present invention, ephedra and gypsum clear lung heat from both the exterior and interior as the main ingredients; coptis chinensis, pinellia ternata, and trichosanthes fruit, inspired by Xiaoxianxiong Decoction, clear heat and resolve phlegm, relieve chest tightness, and dissipate stagnation; tianlizi and jujube are assistant ingredients, clearing away water pathogens; magnolia bark, apricot kernel, and schisandra chinensis assist ephedra in regulating qi and relieving asthma, restoring the lung's functions of dispersing and descending; poria, dried ginger, and asarum are guiding ingredients, dispelling fluid and expelling water; dried ginger and asarum can also counteract the cooling properties of the heat-clearing herbs. The entire prescription works together to clear lung heat and relieve asthma. The Qingjin Pingchuan prescription is primarily based on the Ephedra, Xingren, Shigao, and Gancao Decoction, which treats excessive lung heat, Xiaoxianxiong Decoction, which clears water and resolves heat, Linggan, Wuwei, Jiangxin Decoction, which warms and resolves lung fluid, and Tianli, Dazao Decoction, which relieves lung heat and resolves asthma. These medicines are used together to clear away lung heat and relieve asthma.

[0029] The advantages of the present invention are:

[0030] The traditional Chinese medicine composition provided by the present invention is mainly used to treat severe pneumonia with water and heat intertwined in the chest and diaphragm as the core pathogenesis, has the effects of clearing away lung heat and gradually relieving wheezing. The prescription is relatively simple, effective, and has strong clinical operability. It can effectively relieve early hypoxia of severe pneumonia, improve the patient's oxygenation, and effectively reduce the mortality rate of patients with severe pneumonia. The traditional Chinese medicine prescription of the present invention has a definite therapeutic effect and is more conducive to the improvement of the patient's symptoms, which is of great significance for the treatment of patients with severe pneumonia. DETAILED DESCRIPTION

[0031] The specific implementation methods provided by the present invention are described in detail below with reference to the examples.

[0032] Example 1: Chinese medicine composition of the present invention

[0033] The medicine is composed of the following raw materials in parts by weight: 6 parts of ephedra, 20 parts of gypsum, 10 parts of apricot kernel, 15 parts of poria, 6 parts of dried ginger, 4 parts of asarum, 10 parts of schisandra chinensis, 4 parts of coptis chinensis, 10 parts of pinellia, 10 parts of trichosanthes peel, 10 parts of magnolia bark, 8 parts of scutellaria baicalensis seeds, and 8 parts of jujube.

[0034] Example 2: Chinese medicine composition of the present invention

[0035] The medicine is composed of the following raw materials in parts by weight: 8 parts of ephedra, 25 parts of gypsum, 11 parts of apricot kernel, 18 parts of poria, 8 parts of dried ginger, 5 parts of asarum, 11 parts of schisandra chinensis, 5 parts of coptis chinensis, 12 parts of pinellia, 11 parts of trichosanthes peel, 11 parts of magnolia bark, 9 parts of scutellaria baicalensis seeds and 9 parts of jujube.

[0036] Example 3: Chinese medicine composition of the present invention

[0037] The medicine is composed of the following raw materials in parts by weight: 9 parts of ephedra, 30 parts of gypsum, 12 parts of apricot kernel, 20 parts of poria, 9 parts of dried ginger, 6 parts of asarum, 12 parts of schisandra chinensis, 6 parts of coptis chinensis, 15 parts of pinellia, 12 parts of trichosanthes peel, 12 parts of magnolia bark, 10 parts of scutellaria baicalensis seeds, and 10 parts of jujube.

[0038] Example 4: Chinese medicine composition of the present invention

[0039] The medicine is composed of the following raw materials in parts by weight: 10 parts of ephedra, 35 parts of gypsum, 14 parts of apricot kernel, 24 parts of poria, 10 parts of dried ginger, 7 parts of asarum, 14 parts of schisandra chinensis, 7 parts of coptis chinensis, 18 parts of pinellia, 14 parts of trichosanthes peel, 14 parts of magnolia bark, 11 parts of scutellaria baicalensis seeds, and 11 parts of jujube.

[0040] Example 5: Chinese medicine composition of the present invention

[0041] The medicine is composed of the following raw materials in parts by weight: 12 parts of ephedra, 40 parts of gypsum, 15 parts of apricot kernel, 25 parts of poria, 12 parts of dried ginger, 8 parts of asarum, 15 parts of schisandra chinensis, 8 parts of coptis chinensis, 20 parts of pinellia, 15 parts of trichosanthes peel, 15 parts of magnolia bark, 12 parts of scutellaria baicalensis seeds, and 12 parts of jujube.

[0042] Example 6:

[0043] The preparation method of the traditional Chinese medicine prescription for clearing away heat and relieving asthma of the present invention is as follows:

[0044] Ephedra 9g, Gypsum 30g, Apricot kernel 12g, Poria 20g, Dried ginger 9g, Asarum 6g, Schisandra 12g, Coptis 6g, Pinellia 15g, Trichosanthes peel 12g, Magnolia officinalis 12g, Lemongrass seed 10g, Jujube 10g.

[0045] 1) Weigh each medicinal material according to the raw material ratio, fill a ceramic container with pure water to cover the medicinal materials, and soak the medicinal materials in the water for 30-35 minutes;

[0046] 2) boiling the soaked medicinal materials for the first time, filtering, and collecting the primary filtrate and medicinal residue;

[0047] 3) Add 400-450 mL of water to the residue for secondary decoction, and collect the secondary filtrate;

[0048] 4) Combine the first filtrate and the second filtrate to obtain the Qingjin Pingchuan prescription solution, which is taken in two doses.

[0049] Example 7: Clinical Trial

[0050] A total of 92 SP patients admitted to Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine were randomly divided into two groups in a 1:1 ratio. The treatment group received Qingjin Pingchuan prescription in addition to the treatment plan formulated according to the Chinese Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults (2018 edition), while the control group received only basic treatment for 12 ± 2 days. The mortality rate was observed on day 28.

[0051] (1) Inclusion criteria

[0052] Subjects with a clear diagnosis of SP (referring to the Chinese Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults (2018 edition), meeting the criteria for community-acquired pneumonia and meeting one major criterion or ≥ three minor criteria) were screened. All subjects who met the inclusion criteria and no exclusion criteria (detailed below) were candidates for this study. A total of 92 subjects with severe pneumonia were planned to participate in this study.

[0053] Inclusion criteria were as follows:

[0054] I. Age 18-80 years old;

[0055] II. Meet the criteria for community-acquired pneumonia: ① Community-onset pneumonia; ② Pneumonia-related clinical manifestations: 2.1 New cough, sputum production, or worsening of existing respiratory symptoms, with or without purulent sputum, chest pain, hemoptysis, and dyspnea. 2.2 Fever, body temperature > 37.3°C. 2.3 Signs of pulmonary consolidation and / or moist rales. 2.4 Peripheral blood white blood cell count > 10 × 10 9 / L or <4×10 9 / L, with or without left nuclear shift; ③ Chest X-ray shows new patchy infiltrates, lobar or segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion. (A clinical diagnosis can be established if any of ①, ②, and ③ is met, and tuberculosis, lung tumors, non-infectious interstitial lung disease, pulmonary edema, atelectasis, pulmonary embolism, eosinophilic pulmonary infiltration, and pulmonary vasculitis have been excluded.)

[0056] III. Meet the criteria for severe community-acquired pneumonia: ① Main criteria: 1.1 Requires endotracheal intubation and mechanical ventilation; 1.2 Septic shock requiring vasoactive medications despite active fluid resuscitation. ② Minor criteria: 2.1 Respiratory rate ≥ 30 breaths / min; 2.2 Oxygenation index ≤ 250 mmHg (1 mmHg = 0.133 kPa); 2.3 Multilobar infiltration; 2.4 Impaired consciousness and / or disorientation; 2.5 Blood urea nitrogen ≥ 7.14 mmol / L; 2.6 Systolic blood pressure < 90 mmHg requiring active fluid resuscitation. (Those who meet the criteria for community-acquired pneumonia and meet one of the following main criteria or ≥ three of the following minor criteria can be diagnosed with severe pneumonia.)

[0057] IV. The acute attack lasts for less than 3 days;

[0058] V. Informed consent.

[0059] (2) Exclusion criteria

[0060] ① Those with allergic constitution or allergic to known ingredients of this drug;

[0061] ② Psychiatric patients;

[0062] ③Patients with lung abscess;

[0063] ④ Patients with combined malignant tumors;

[0064] ⑤ HIV-positive patients;

[0065] ⑥ Those who do not meet the inclusion criteria, do not use the medication as prescribed, cannot be judged for efficacy or have incomplete data, etc., which affects the judgment of efficacy or safety.

[0066] (3) Rejection, shedding and termination test standards:

[0067] Patients may terminate or withdraw from the trial at any time, and their data before withdrawal will also be included in the experimental analysis. The criteria for exclusion, dropout and termination of the trial are as follows:

[0068] ①Serious adverse events occur;

[0069] ②Serious complications occur during the trial;

[0070] ③ Those who violated the research protocol and did not receive treatment according to the protocol after inclusion;

[0071] ④The patient requests to withdraw from the trial;

[0072] ⑤Patients who were lost to follow-up or did not come to the hospital for follow-up on time.

[0073] (4) General

[0074] A total of 92 patients with severe pneumonia were enrolled, including 46 in the treatment group and 46 in the control group. After treatment with Qingjin Pingchuan Decoction, 34 patients in the treatment group survived on day 28, 8 patients died, and 4 patients dropped out during treatment. In the control group, 25 patients survived on day 28, 16 patients died, and 5 patients dropped out during treatment.

[0075] (5) Results

[0076] The 28-day mortality rate in the control group was 39.02% (16 / 41), and the 28-day mortality rate in the TCM intervention group was 19.05% (8 / 42). Compared with the TCM group, the 28-day mortality rate in the control group was higher, and the difference was statistically significant (P=0.045<0.05).

[0077] The hospitalization time of the control group was 14 [10.00; 19.00] days, and that of the TCM group was 9 [7.00; 15.00] days. The hospitalization time of the TCM group was shorter than that of the control group, and the difference was statistically significant (P=0.019<0.05).

[0078] The mechanical ventilation time in the TCM group was 0 [0.00; 0.75] days, and the treatment time in the control group was 0.00 [0.00; 6.00] days. The mechanical ventilation time in the TCM group was shorter than that in the control group, and the difference was statistically significant (P = 0.035 < 0.05).

[0079] After receiving Qingjin Pingchuan prescription treatment, the TCM syndrome efficacy in the TCM group was effective within 28 days. A total of 38 cases in the TCM group were cured, including 5 cases (11.90%), 20 cases (47.62%) with marked effect, and 13 cases (30.95%) with effective effect. A total of 21 cases in the control group were effective, including 1 case (2.44%) with cure, 8 cases (19.51%) with marked effect, and 12 cases (29.27%) with effective effect. The TCM syndrome efficacy of the two groups was more conducive to the improvement of the patients' symptoms, and the difference was statistically significant (P < 0.05). There was no statistically significant difference in liver and kidney function, vital signs and other indicators between the two groups before and after treatment (P > 0.05). No adverse events occurred in either group during the monitoring treatment period, indicating that Qingjin Pingchuan prescription is safe for the treatment of patients with severe pneumonia.

[0080] (6) Conclusion

[0081] A comparison of before and after treatment of patients with severe pneumonia, characterized by water-heat accumulation in the chest and diaphragm, demonstrates the definite efficacy of the key formula of the present invention, demonstrating its effectiveness in reducing mortality in patients with severe pneumonia. The present invention is relatively simple and clinically feasible, and is of great significance for the treatment of patients with severe pneumonia.

[0082] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the described embodiments. Those skilled in the art may make various equivalent modifications or substitutions without departing from the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. A Chinese medicine composition for treating severe pneumonia, characterized in that: It is composed of the following raw materials in parts by weight: 6-12 parts of ephedra, 20-40 parts of gypsum, 10-15 parts of apricot kernel, 15-25 parts of poria, 6-12 parts of dried ginger, 4-8 parts of asarum, 10-15 parts of schisandra chinensis, 4-8 parts of coptis chinensis, 10-20 parts of pinellia, 10-15 parts of trichosanthes peel, 10-15 parts of magnolia bark, 8-12 parts of scutellaria baicalensis seeds, and 8-12 parts of jujube.

2. The Chinese medicine composition for treating severe pneumonia according to claim 1, characterized in that It is composed of the following raw materials in parts by weight: 9-12 parts of ephedra, 30-40 parts of gypsum, 12-15 parts of apricot kernel, 20-25 parts of poria, 9-12 parts of dried ginger, 6-8 parts of asarum, 12-15 parts of schisandra chinensis, 6-8 parts of coptis chinensis, 15-20 parts of pinellia, 12-15 parts of trichosanthes peel, 12-15 parts of magnolia bark, 10-12 parts of scutellaria baicalensis seeds, and 10-12 parts of jujube.

3. The Chinese medicine composition for treating severe pneumonia according to claim 1, characterized in that It is composed of the following raw materials in parts by weight: 9 parts of Ephedra, 30 parts of Gypsum, 12 parts of Apricot Kernel, 20 parts of Poria, 9 parts of Dry Ginger, 6 parts of Asarum, 12 parts of Schisandrae Chinensis, 6 parts of Coptis Rhizome, 15 parts of Pinellia, 12 parts of Fructus Trichosanthis, 12 parts of Magnolia Bark, 10 parts of Lecithin Seeds, and 10 parts of Jujube.

4. The Chinese medicine composition for treating severe pneumonia according to any one of claims 1 to 3, characterized in that The severe pneumonia is a severe pneumonia with the core pathogenesis being the interaction of water and heat in the chest and diaphragm.

5. A method for preparing a traditional Chinese medicine composition for treating severe pneumonia according to any one of claims 1 to 4, characterized in that: The following steps are involved: a) Weigh each medicinal material according to the raw material ratio, add pure water to cover the medicinal materials, and soak the medicinal materials in the water for 30-35 minutes; b) boiling the soaked medicinal materials for the first time, filtering, and collecting the primary filtrate and medicinal residues; c) adding 400-450 mL of water to the medicinal residue for secondary decoction, and collecting the secondary filtrate; d) combining the primary filtrate and the secondary filtrate to obtain the Chinese medicine composition liquid.

6. A Chinese medicine preparation comprising the Chinese medicine composition for treating severe pneumonia according to any one of claims 1 to 4 as an active ingredient, characterized in that: The Chinese medicine preparation is prepared into a common dosage form in pharmacy by conventional preparation methods in the art.

7. The Chinese medicine preparation according to claim 6, characterized in that The dosage form of the traditional Chinese medicine preparation is decoction, tablet, capsule, granule, pill, mixture, oral liquid or syrup.

8. The Chinese medicine preparation according to claim 6, characterized in that The traditional Chinese medicine preparation also includes pharmaceutically acceptable excipients.

9. Use of the traditional Chinese medicine composition according to any one of claims 1 to 4 in the preparation of a medicament for treating severe pneumonia.

10. Use of the traditional Chinese medicine preparation according to any one of claims 6 to 8 in preparing a medicament for treating severe pneumonia.